News
Stay up to date with Sintetica’s latest news.
Sintetica announces the appointment of Brendan O’Grady as an independent director to its Board of Directors
Mr. O’Grady brings more than 30 years of experience in the pharmaceutical industry, with significant commercial expertise in specialty/innovative, generics, biologic, and bio-similar products…
Unveiling Our New Swiss Website
Exciting news for our Swiss community! We're thrilled to announce the launch of our dedicated Swiss website…
We are pleased to announce that Dr. Hubert Puech d'Alissac has been appointed Executive Chairman of the Board of Sintetica
Along his diverse career path, Dr Puech d'Alissac has held positions of high responsibility in Europe, Africa, Asia and North America. His extensive knowledge and proven track record enable him to bring a broad strategic vision and considerable operational capabilities to Sintetica…
New FDA approval for Swiss pharmaceutical company Sintetica. Couvet production site is ready for the US market.
Sintetica's other production site in Couvet, which has been completely renovated thanks to considerable investments in recent years, has also been approved by the US Federal Drug Administration (FDA)…
Sintetica established its subsidiary Sintetica US
Sintetica, a Swiss pharmaceutical company headquartered in Mendrisio and specialized in the production of injectable medicines in the field of pain therapy…
Harrow Announces U.S. FDA Approval of IHEEZO™
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia…
Congratulations to the new CEO Nicola Caronzolo
We are very happy to announce that Dr. Nicola Caronzolo has been appointed as the new CEO of Sintetica…
